EurekaMag.com logo
+ Site Statistics
References:
53,623,987
Abstracts:
29,492,080
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Treatment naive HIV-1 infected patients respond immunologically when administered HE2000; results from a phase I/II clinical trial



Treatment naive HIV-1 infected patients respond immunologically when administered HE2000; results from a phase I/II clinical trial



Antiviral Research 46(1): A49, April




(PDF 0-2 workdays service: $29.90)

Accession: 035980297

Download citation: RISBibTeXText



Related references

Efficacy and safety of lersivirine (UK-453,061) versus efavirenz in antiretroviral treatment-naive HIV-1-infected patients: week 48 primary analysis results from an ongoing, multicenter, randomized, double-blind, phase IIb trial. Journal of Acquired Immune Deficiency Syndromes 62(2): 171-179, 2013

Efficacy and safety of darunavir/ritonavir at 48 weeks in treatment-naïve, HIV-1-infected adolescents: results from a phase 2 open-label trial (DIONE). Pediatric Infectious Disease Journal 33(9): 940-945, 2015

Modified directly observed antiretroviral therapy compared with self-administered therapy in treatment-naive HIV-1-infected patients: a randomized trial. Archives of Internal Medicine 169(13): 1224-1232, 2009

Long-term efficacy, safety, and tolerability of rilpivirine (RPV, TMC278) in HIV type 1-infected antiretroviral-naive patients: week 192 results from a phase IIb randomized trial. Aids Research and Human Retroviruses 28(5): 437-446, 2012

NK-like CD8+ cells in immunologically naive neonatal calves that respond to dendritic cells infected with Mycobacterium bovis BCG. Journal of Leukocyte Biology 71(2): 184-194, February, 2002

SILEN-C3, a phase 2 randomized trial with faldaprevir plus pegylated interferon α-2a and ribavirin in treatment-naive hepatitis C virus genotype 1-infected patients. Antimicrobial Agents and ChemoTherapy 58(6): 3429-3436, 2014

Directly administered antiretroviral therapy for HIV-infected individuals in opioid treatment programs: results from a randomized clinical trial. Plos One 8(7): E68286-E68286, 2014

Phase 2 double-blind, randomized trial of etravirine versus efavirenz in treatment-naive patients: 48-week results. Aids 25(18): 2249-2258, 2012

A Single-dose Zoledronic Acid Infusion Prevents Antiretroviral Therapy-induced Bone Loss in Treatment-naive HIV-infected Patients: A Phase IIb Trial. Clinical Infectious Diseases 63(5): 663-671, 2016

Clinical Trial Report: TMC278 (Rilpivirine) Versus Efavirenz as Initial Therapy in Treatment-Naïve, HIV-1-Infected Patients. Current Infectious Disease Reports 13(1): 1-3, 2011

AT-101, a small molecule Bcl-2 antagonist, in treatment naïve CLL patients (pts) with high risk features; Preliminary results from an ongoing phase I trial. Journal of Clinical Oncology 24(18_suppl): 6605-6605, 2016

Efficacy and safety of teverelix la, a new GNRH antagonist in patients with benign prostatic hyperplasia (BPH). Results from a phase II randomised, double-blind, placebo-controlled, multicentre, multinational study investigating two single injections of 30 mg or 60 mg (separated by at least 12 weeks) administered sc to treatment naive patients suffering from BPH. European Urology Supplements 7(3): 170, 2008

Potent antiretroviral activity of dOTC in HIV-1-infected patients Initial results from a phase I/II clinical trial. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 39: 471, 1999

Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: pooled results from the phase 3 double-blind randomized ECHO and THRIVE Trials. Journal of Acquired Immune Deficiency Syndromes 60(1): 33-42, 2012